iShares Genomics Immunology and Healthcare ETF (IDNA) Dividend Yield, History & Forecast

iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. It pays a current dividend yield of 0.87% ($0.28 per share annually (TTM)). The most recent ex-dividend date was June 15, 2026, with payment scheduled for June 18, 2026. market capitalization is approximately $150M.

IDNA fund composition

IDNA holds 50 positions, with 42.9% of assets in its ten largest. It charges an expense ratio of 0.47%, and manages $193.6M.

Top 10 holdings

HoldingWeight
BAYN.DEBAYER AG4.77%
TWSTTWIST BIOSCIENCE CORP4.72%
RVMDREVOLUTION MEDICINES INC4.61%
MRNAMODERNA INC4.37%
INCYINCYTE CORP4.30%
4502.TTAKEDA PHARMACEUTICAL LTD4.18%
REGNREGENERON PHARMACEUTICALS INC4.16%
GMAB.COGENMAB4.12%
VRTXVERTEX PHARMACEUTICALS INC3.86%
MRKMERCK & CO INC3.85%

Sector allocation

Healthcare100.0%Industrials0.3%Cash & Others0.2%

Frequently Asked Questions about iShares Genomics Immunology and Healthcare ETF (IDNA)

What is iShares Genomics Immunology and Healthcare ETF's dividend yield?
iShares Genomics Immunology and Healthcare ETF (IDNA) pays a current trailing twelve-month dividend yield of 0.87%, which works out to $0.28 per share annually based on the most recent payout schedule.
When does iShares Genomics Immunology and Healthcare ETF pay distributions?
The most recent ex-dividend date was June 15, 2026. The next scheduled dividend payment date is June 18, 2026.
How many years has iShares Genomics Immunology and Healthcare ETF increased its dividend?
iShares Genomics Immunology and Healthcare ETF (IDNA) has increased its dividend for 1 consecutive year.
What does iShares Genomics Immunology and Healthcare ETF invest in?
The iShares Genomics Immunology and Healthcare ETF (IDNA) is designed to mirror the investment performance of a specific index. This index comprises companies operating in both mature and emerging global markets. These businesses are strategically chosen for their potential to capitalize on sustained innovation and expansion within the crucial fields of genomics, immunology, and bioengineering.